ArticleFrontiers in oncology2026

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.

Gi-June Min et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.